PDS Biotech to Present at the Virtual Fall Investor Summit on November 16th-18th

Rhea-AI Summary

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company, announced that CEO Dr. Frank Bedu-Addo will present at the virtual Fall Investor Summit on November 16, 2020, at 10:30 AM Eastern Time. This event features 75 companies and connects them with over 300 institutional and retail investors. A replay of the presentation will be available in the investor relations section of the Company’s website. PDS Biotech specializes in cancer therapies and infectious disease vaccines using its proprietary Versamune technology.

NEW YORK, NY / ACCESSWIRE / November 13, 2020 / PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune^® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, Chief Executive Officer, will be presenting at this year's virtual Fall Investor Summit taking place November 16^th-18^th, 2020.

The Company's presentation will take place on Monday, November 16th at 10:30am Eastern Time. A replay of the presentation will be available online in the investor relations section of the Company's website. The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune^® T-cell activating technology platform. Versamune^® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company: please contact Brittney Blocker (brittney@investorsummitgroup.com)

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

For more information about the Investor Summit

Please visit: www.investorsummitgroup.com

Or, contact Brittney Blocker at brittney@investorsummitgroup.com

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotechnology
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Jacob Goldberger
CG Capital
Phone: +1 (404) 736-3841
Email: jacob@cg.capital

News Compliments of ACCESSWIRE

SOURCE: PDS Biotechnology Corporation

View source version on accesswire.com:
https://www.accesswire.com/616532/PDS-Biotech-to-Present-at-the-Virtual-Fall-Investor-Summit-on-November-16th-18th

FAQ

What is PDS Biotechnology Corporation's stock symbol?

PDS Biotechnology Corporation's stock symbol is PDSB.

When will PDS Biotechnology present at the Fall Investor Summit?

PDS Biotechnology will present at the Fall Investor Summit on November 16, 2020, at 10:30 AM Eastern Time.

Where can I watch the PDSB presentation from the Fall Investor Summit?

The presentation can be watched online in the investor relations section of PDS Biotechnology's website.

What technologies does PDS Biotechnology focus on?

PDS Biotechnology focuses on immunotherapy technologies, specifically its proprietary Versamune technology for cancer therapies and infectious disease vaccines.

How many companies are participating in the Fall Investor Summit?

The Fall Investor Summit features 75 participating companies.